Immunic, Inc. (IMUX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IMUX SEC filings page.
This page shows Immunic, Inc. (IMUX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Immunic remains a development-stage cash consumer, with financing supporting research while the balance sheet moves into negative equity.
In FY2025, operating cash flow of-$85.8M remained close to the net loss of$97.2M , while free cash flow was nearly identical at-$86.0M . That combination indicates the reported loss largely reflects cash spending rather than heavy capital investment or a large noncash accounting gap.
Research and development consumed
Financing provided
Financial Health Signals
Immunic, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Immunic, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Immunic, Inc. reported a net loss of $97.2M while operations used $85.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Immunic, Inc.'s EBITDA was -$35.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 30.5% from the same quarter a year earlier. Against the prior quarter it is down 6.3%.
Immunic, Inc. reported -$34.1M in net income in Q2 2026. This represents a decrease of 27.1% from the same quarter a year earlier. Against the prior quarter it is down 4.6%.
Not reported for Q2 2026.
Cash & Balance Sheet
Immunic, Inc. recorded an outflow of $31.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 26.8% from the same quarter a year earlier. Against the prior quarter it is down 80.6%.
Immunic, Inc. held $155.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Immunic, Inc.'s ROE was -26.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 52.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Immunic, Inc. invested $25.9M in research and development in Q2 2026. This represents an increase of 21.3% from the same quarter a year earlier. Against the prior quarter it is up 1.2%.
Immunic, Inc. invested $249K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 591.7% from the same quarter a year earlier. Against the prior quarter it is up 12350.0%.
Not reported for Q2 2026.
IMUX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $25.9M+21.3% | $25.6M+19.0% | N/A | $20.0M-6.4% | $21.4M+16.6% | $21.5M+14.9% | N/A | $21.4M+8.0% |
| SG&A Expenses | $9.4M+64.4% | $7.6M+43.8% | N/A | $6.0M+37.3% | $5.7M+27.2% | $5.3M+2.9% | N/A | $4.4M+15.4% |
| Operating Income | -$35.3M-30.4% | -$33.2M-23.9% | N/A | -$26.0M-1.0% | -$27.1M-18.7% | -$26.8M-12.3% | N/A | -$25.7M-9.1% |
| EBITDA | -$35.3M-30.5% | -$33.2M-24.0% | N/A | -$26.0M-1.0% | -$27.0M-18.7% | -$26.8M-12.3% | N/A | -$25.7M-9.1% |
| Net Income | -$34.1M-27.1% | -$32.6M-27.9% | N/A | -$25.6M-5.0% | -$26.8M-25.4% | -$25.5M+13.9% | N/A | -$24.4M-7.0% |
| EPS (Basic) | -$0.80+60.6% | -$1.08+57.0% | -$0.07+72.0% | -$0.13+45.8% | -$2.03-866.7% | -$2.51-736.7% | -$0.25+47.9% | -$0.24+52.9% |
| EPS (Diluted) | -$0.80 | -$1.08 | -$0.07+72.0% | -$0.13 | -$2.03 | -$2.51 | -$0.25+47.9% | -$0.24 |
| Diluted Shares (Avg) | 43M | 30M | N/A | 194M | 13M | 10M | N/A | 101M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
IMUX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $159.2M+159.1% | $189.7M+824.9% | $24.1M-41.1% | $40.7M-37.1% | $61.4M-29.0% | $20.5M-80.3% | $40.9M-24.7% | $64.8M-3.3% |
| Current Assets | $157.8M+163.7% | $188.8M+894.8% | $22.9M-41.9% | $39.3M-37.9% | $59.8M-29.6% | $19.0M-81.5% | $39.3M-25.1% | $63.3M-3.0% |
| Cash & Equivalents | $155.1M+180.4% | $186.6M+1204.7% | $15.5M-56.6% | $35.1M-40.5% | $55.3M-30.6% | $14.3M-85.3% | $35.7M-23.6% | $59.1M-1.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $31.6M+14.8% | $38.5M+49.2% | $30.7M+36.9% | $30.2M+28.3% | $27.5M+20.1% | $25.8M+25.4% | $22.4M-11.5% | $23.5M+26.8% |
| Current Liabilities | $31.3M+14.5% | $38.4M+49.9% | $30.6M+38.1% | $30.1M+28.8% | $27.3M+20.4% | $25.6M+27.0% | $22.2M-10.3% | $23.4M+31.4% |
| Non-Current Liabilities | $328K+60.0% | $146K-30.5% | $107K-59.5% | $126K-32.3% | $205K-14.9% | $210K-51.5% | $264K-58.7% | $186K-76.4% |
| Total Equity | $127.6M+276.2% | $151.2M+2960.5% | -$6.7M-136.2% | $10.5M-74.5% | $33.9M-46.7% | -$5.3M-106.3% | $18.4M-36.3% | $41.2M-14.8% |
| Retained Earnings | -$675.3M-19.8% | -$641.2M-19.4% | -$608.6M-19.0% | -$589.3M-21.2% | -$563.7M-22.0% | -$536.9M-21.9% | -$511.4M-24.5% | -$486.2M-24.9% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
IMUX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$31.0M-26.0% | -$17.3M+20.6% | -$19.3M+16.0% | -$20.1M+3.1% | -$24.6M-44.4% | -$21.8M+9.1% | -$23.0M-63.7% | -$20.8M-20.1% |
| Depreciation & Amortization | $34K-20.9% | $33K-23.3% | $42K+20.0% | $40K-4.8% | $43K+38.7% | $43K+65.4% | $35K+52.2% | $42K+23.5% |
| Stock-Based Compensation | $6.8B+257.1% | $4.5M+118.7% | N/A | N/A | $1.9B | $2.0M-25.7% | N/A | N/A |
| Capital Expenditures | $249K+591.7% | $2K-95.7% | $11K+266.7% | $67K+34.0% | $36K-80.0% | $47K+51.6% | $3K-98.2% | $50K+13.6% |
| Free Cash Flow | -$31.2M-26.8% | -$17.3M+20.7% | -$19.3M+16.0% | -$20.2M+3.1% | -$24.6M-43.1% | -$21.8M+9.1% | -$23.0M-61.8% | -$20.8M-20.1% |
| Investing Cash Flow | -$249K-591.7% | -$2K+95.7% | -$11K-266.7% | -$67K-34.0% | -$36K+80.0% | -$47K-51.6% | -$3K+98.2% | -$50K-13.6% |
| Financing Cash Flow | $118K-99.8% | $188.6M | $59K-23.4% | $0 | $65.5M | $0-100.0% | $77K-87.3% | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
IMUX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -26.7%+52.4pp | -21.6% | N/A | -243.6%-184.5pp | -79.1%-45.5pp | N/A | N/A | -59.1%-12.1pp |
| Return on Assets | -21.4%+22.2pp | -17.2%+107.0pp | N/A | -62.8%-25.2pp | -43.7%-18.9pp | -124.2%-95.8pp | N/A | -37.6%-3.6pp |
| Current Ratio | 5.05+2.9x | 4.92+4.2x | 0.75-1.0x | 1.31-1.4x | 2.19-1.6x | 0.74-4.4x | 1.77-0.4x | 2.71-1.0x |
| Debt-to-Equity | 0.25-0.6x | 0.25 | N/A | 2.88+2.3x | 0.81+0.5x | N/A | 1.22+0.3x | 0.57+0.2x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$6.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.75), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Immunic, Inc. IMUX | FY2025 | N/A | -$97.2M | N/A | $106.7M | — |
| Atara Biotherapeutics, Inc ATRA | FY2025 | $120.8M | $32.7M | 27.1% | $94.4M | 63/100 |
| CervoMed Inc. CRVO | FY2025 | $4.0M | -$27.0M | N/A | $50.0M | 45/100 |
| Opus Genetics, Inc. IRD | FY2025 | $14.2M | -$49.6M | N/A | $364.4M | 38/100 |
| Acumen Pharmaceuticals, Inc. ABOS | FY2025 | N/A | -$121.3M | N/A | $154.0M | — |
Where Immunic, Inc. Ranks
Frequently Asked Questions
Is Immunic, Inc. profitable?
No, Immunic, Inc. (IMUX) reported a net income of -$97.2M in fiscal year 2025.
What is Immunic, Inc.'s EBITDA?
Immunic, Inc. (IMUX) had EBITDA of -$103.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Immunic, Inc.'s free cash flow?
Immunic, Inc. (IMUX) recorded an outflow of $86.0M in free cash flow during fiscal year 2025. This represents a -1.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Immunic, Inc.'s operating cash flow?
Immunic, Inc. (IMUX) recorded an outflow of $85.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Immunic, Inc.'s total assets?
Immunic, Inc. (IMUX) had $24.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Immunic, Inc.'s capital expenditures?
Immunic, Inc. (IMUX) invested $161K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Immunic, Inc. spend on research and development?
Immunic, Inc. (IMUX) invested $82.0M in research and development during fiscal year 2025.
What is Immunic, Inc.'s current ratio?
Immunic, Inc. (IMUX) had a current ratio of 0.75 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Immunic, Inc.'s return on assets (ROA)?
Immunic, Inc. (IMUX) had a return on assets of -404.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Immunic, Inc.'s P/E ratio?
Immunic, Inc. (IMUX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $106.7M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Immunic, Inc.'s price-to-sales ratio?
Immunic, Inc. (IMUX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $106.7M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Immunic, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Immunic, Inc. (IMUX) held $15.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $85.8M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Immunic, Inc.'s debt-to-equity ratio negative or not reported?
Immunic, Inc. (IMUX) has negative shareholder equity of -$6.7M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Immunic, Inc.'s Piotroski F-Score?
Immunic, Inc. (IMUX) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Immunic, Inc.'s earnings high quality?
Immunic, Inc. (IMUX) reported a net loss of $97.2M while operations used $85.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.